1
Initial treatment showed improved PFS compared to recurrent treatment, and both showed similar OS.
2
Conclusion: Postoperative radiotherapy after resection of MPE was associated with improved PFS and LC.
3
Reversal of hypermethylation was seen in a subset of patients and correlated with improved PFS.
4
This combination significantly improved PFS and OS in responders.
5
At multivariate analysis high CD20BG was also an independent prognostic factor of improved PFS and OS.
6
Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.
7
Among MBs, nodularity may be an important prognostic factor for improved PFS and OS in infants and children.
8
In those with grade 3 EEC, adjuvant chemotherapy with or without radiation improved PFS compared to observation or radiation alone.
9
Additionally, low residual FDG and FLT uptake early and late in the course of erlotinib treatment is associated with improved PFS.
10
In contrast, mutations in previously unreported HVCN1, a voltage-gated proton channel-encoding gene and B-cell receptor signaling modulator, were associated with improved PFS.
11
The addition of vandetanib to chemotherapy significantly improves PFS in patients with locally advanced or metastatic cancers, especially lung and thyroid cancer.
12
The addition of lapatinib significantly improved PFS for this patient subgroup and augments data supporting interaction between steroid hormone and peptide hormone signaling.
13
Conclusions: Compared with non-platinum-based chemotherapy, the first-line platinum-based chemotherapy can improve PFS and OS in TNBC patients with metastases confined to the lungs.
14
Our data support the use of hypomethylating agents before allo-SCT for patients with CMML to achieve morphologic remission and improve PFS of these patients.
15
Conclusion: Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS.